Cargando…
Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
OBJECTIVES: In this paper, we outline and compare pharmaceutical pricing and reimbursement policies for in-patent prescription medicines in three Maghreb countries, Algeria, Morocco, and Tunisia, and explore possible improvements in their pricing and reimbursement systems. METHODS: The evidence info...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Routledge
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443953/ https://www.ncbi.nlm.nih.gov/pubmed/37614557 http://dx.doi.org/10.1080/20016689.2023.2244304 |
_version_ | 1785093949017292800 |
---|---|
author | Dahmani, Hajer Fradi, Ines Achour, Leila Toumi, Mondher |
author_facet | Dahmani, Hajer Fradi, Ines Achour, Leila Toumi, Mondher |
author_sort | Dahmani, Hajer |
collection | PubMed |
description | OBJECTIVES: In this paper, we outline and compare pharmaceutical pricing and reimbursement policies for in-patent prescription medicines in three Maghreb countries, Algeria, Morocco, and Tunisia, and explore possible improvements in their pricing and reimbursement systems. METHODS: The evidence informing this study comes from both an extensive literature review and a primary data collection from experts in the three studied countries. KEY FINDINGS: Twenty-six local experts where interviewed Intervieweesincluded ministry officials, representatives of national regulatory authorities, health insurance organizations, pharmaceutical procurement departments and agencies, academics, private pharmaceutical-sector actors, and associations. Results show that External Reference Pricing (ERP) is the dominant pricing method for in-patent medicines in the studied countries. Value-based pricing through Health Technology Assessment (HTA) is a new concept, recently used in Tunisia to help the reimbursement decision of some in-patent medicines but not yet used in the pricing of innovative medicines in the studied countries. Reimbursement decision is mainly based on negotiations set on Internal Reference Pricing (IRP). CONCLUSION: Whereas each country has its specific regulations, there are many similarities in the pricing and reimbursement policies of in-patent medicines in Algeria, Morocco, and Tunisia. The ERP was found to be the dominant method to inform pricing and reimbursement decisions of in-patent medicines. Countries in the region can focus on the development of explicit value assessment systems and minimize their dependence on ERP over the longer-term. In this context, HTA will rely on local assessment of the evidence. |
format | Online Article Text |
id | pubmed-10443953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Routledge |
record_format | MEDLINE/PubMed |
spelling | pubmed-104439532023-08-23 Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis Dahmani, Hajer Fradi, Ines Achour, Leila Toumi, Mondher J Mark Access Health Policy Review Article OBJECTIVES: In this paper, we outline and compare pharmaceutical pricing and reimbursement policies for in-patent prescription medicines in three Maghreb countries, Algeria, Morocco, and Tunisia, and explore possible improvements in their pricing and reimbursement systems. METHODS: The evidence informing this study comes from both an extensive literature review and a primary data collection from experts in the three studied countries. KEY FINDINGS: Twenty-six local experts where interviewed Intervieweesincluded ministry officials, representatives of national regulatory authorities, health insurance organizations, pharmaceutical procurement departments and agencies, academics, private pharmaceutical-sector actors, and associations. Results show that External Reference Pricing (ERP) is the dominant pricing method for in-patent medicines in the studied countries. Value-based pricing through Health Technology Assessment (HTA) is a new concept, recently used in Tunisia to help the reimbursement decision of some in-patent medicines but not yet used in the pricing of innovative medicines in the studied countries. Reimbursement decision is mainly based on negotiations set on Internal Reference Pricing (IRP). CONCLUSION: Whereas each country has its specific regulations, there are many similarities in the pricing and reimbursement policies of in-patent medicines in Algeria, Morocco, and Tunisia. The ERP was found to be the dominant method to inform pricing and reimbursement decisions of in-patent medicines. Countries in the region can focus on the development of explicit value assessment systems and minimize their dependence on ERP over the longer-term. In this context, HTA will rely on local assessment of the evidence. Routledge 2023-08-20 /pmc/articles/PMC10443953/ /pubmed/37614557 http://dx.doi.org/10.1080/20016689.2023.2244304 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
spellingShingle | Review Article Dahmani, Hajer Fradi, Ines Achour, Leila Toumi, Mondher Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis |
title | Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis |
title_full | Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis |
title_fullStr | Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis |
title_full_unstemmed | Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis |
title_short | Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis |
title_sort | pharmaceutical pricing and reimbursement policies in algeria, morocco, and tunisia: comparative analysis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443953/ https://www.ncbi.nlm.nih.gov/pubmed/37614557 http://dx.doi.org/10.1080/20016689.2023.2244304 |
work_keys_str_mv | AT dahmanihajer pharmaceuticalpricingandreimbursementpoliciesinalgeriamoroccoandtunisiacomparativeanalysis AT fradiines pharmaceuticalpricingandreimbursementpoliciesinalgeriamoroccoandtunisiacomparativeanalysis AT achourleila pharmaceuticalpricingandreimbursementpoliciesinalgeriamoroccoandtunisiacomparativeanalysis AT toumimondher pharmaceuticalpricingandreimbursementpoliciesinalgeriamoroccoandtunisiacomparativeanalysis AT pharmaceuticalpricingandreimbursementpoliciesinalgeriamoroccoandtunisiacomparativeanalysis |